Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies

Deng-Chyang Wu, Ping-I Hsu, Hui-Hwa Tseng, Feng-Woei Tsay, Kwok-Hung Lai, Chao-Hung Kuo, Sheng-Wen Wang, Angela Chen, Deng-Chyang Wu, Ping-I Hsu, Hui-Hwa Tseng, Feng-Woei Tsay, Kwok-Hung Lai, Chao-Hung Kuo, Sheng-Wen Wang, Angela Chen

Abstract

Antibiotic resistance to amoxicillin in second-line eradication therapy for Helicobacter pylori infection is much less frequent than resistance to metronidazole. We conducted a randomized, controlled study to compare the efficacies of standard quadruple rescue therapy and a new therapy with amoxicillin replacing metronidazole for patients failing first-line eradication treatment. We randomly assigned 120 patients who failed H. pylori eradication using a proton pump inhibitor plus clarithromycin and amoxicillin to undergo a 1-week rescue therapy with esomeprazole, bismuth subcitrate, and tetracycline plus either metronidazole (EBTM group, n = 62) or amoxicillin (EBTA group, n = 58). We used follow-up endoscopy 8 weeks after the end of treatment to assess the treatment response. We also examined and analyzed antibiotic resistances and CYP2C19 genotypes. Intention-to-treat analysis demonstrated that the EBTA group had a significantly lower eradication rate than the EBTM group (62% vs. 81%, respectively, p = 0.02). Per-protocol analysis showed similar results (64% vs. 83%, p = 0.01). However, the EBTA group had less frequency of adverse events than the EBTM group (19% vs. 44%, p < 0.01). Both groups had good drug compliance (both 97%). Antibiotic susceptibility tests showed that the frequency of amoxicillin-resistant strains was much less than that of metronidazole-resistant strains (0% vs. 54%, respectively), and there were no significant differences between H. pylori eradication rates and antibiotic resistances. In conclusion, EBTA quadruple therapy demonstrated a lower eradication rate than standard EBTM therapy in second-line rescue treatment. The discrepancy between in vitro antibiotic susceptibility and in vivo eradication response is probably due to drug interactions between combined antibiotics or some unknown causes, and should not be neglected in H. pylori therapy.

References

    1. Di Mario F, Cavallaro LG, Scarpignato C. "Rescue" therapies for the management of Helicobacter pylori infection. Dig Dis. 2006;24:113-130.
    1. Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter. 2009;14(Suppl 1):46-51.
    1. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14:5385-5402.
    1. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized controlled study. Ann Intern Med. 1992;116:705-708.
    1. Graham DY, Lew GM, Ramirez FC, Genta RM, Klein PD, Malaty HM. A nonmetronidazole triple therapy for eradication of Helicobacter pylori infection-tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993;7:111-113.
    1. Hong L, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology. 2005;128:833-848.
    1. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systemic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047-1055.
    1. Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, Kim JG, Osato MS, Graham DY, Yamaoka Y. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol. 2002;97:2231-2238.
    1. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, Tsai WL, Wu CJ, Lo CC, Tseng HH, Yamaoka Y, Chen JL, Lo GH. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005;100:2387-2392.
    1. Hsu PI, Lai KH, Tseng HH, Liu YC, Yen MY, Lin CK, Lo GH, Huang RL, Huang JS, Cheng JS, Huang WK, Ger LP, Chen W, Hsu PN. Correlation of serum immunoglobulin G Helicobacter pylori antibody titers with histologic and endoscopic findings in patients with dyspepsia. J Clin Gastroenterol. 1997;25:587-591.
    1. Hsu PI, Lai KH, Wu CJ, Tseng HH, FW Tasy, NJ Peng, Chen TA, Chuah SK, Lin WS, Lo GH. High-dose verus low-dose esomeprazole-based triple therapy for Helicobacter pylori infecton. Eur J Clin Invest. 2007;37:724-730.
    1. Hsu PI, Wu DC, Chen A, Peng NJ, Tseng HH, Tsay FW, Lo GH, Lu CY, Yu FJ, Lai KH. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest. 2008;38:404-409.
    1. Hunt RH, Lam SK. Helicobacter pylori: from art to a science. J Gastroenterol Hepatol. 1998;13:21-28.
    1. Kita T, Sakaeda T, Aoyama N, Sakai T, Kawahara Y, Kasuga M, Okumura K. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull. 2002;25:923-927.
    1. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC. Efficacy of levofloxacin-based triple therapy for Heliocbacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother. 2009;63:1017-1024.
    1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut. 2007;56:772-781.
    1. Megraud F, Lamouliatte H. The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:1333-1343.
    1. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101:1467-1475.
    1. Pavicic MJ, Namavar F, Verboom T, Winkelhoff AJ, De Graaff J. In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations. Antimicrob Agents Chemother. 1993;37:1184-1186.
    1. Peng NJ, Lee SC, Tsay DG, Lo CC, Tseng HH, Huang WK, Lo GH, Hsu PI. Clinical significance of oral urease in the diagnosis of H. pylori infection by 13C-urea breath test. Dig Dis Sci. 2001;46:1773-1778.
    1. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor for treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004;76:201-209.
    1. Sorice F, Ortona L, Pizzigallo E. Further aspects of combination antibiotic therapy. Critical review and personal case studies. Minerva Med. 1975;66:2805-2822.
    1. Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am. 2000;29:819-827.
    1. Wu DC, Hsu PI, Chen A, Lai KH, Tsay FW, Wu CJ, Lo GH, Wu JY, Wu IC, Wang WM, Tseng HH. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest. 2006;36:803-809.
    1. Wu IC, Wu DC, Hsu PI, Lu CY, Yu FJ, Wang TE, Chang WH, Chen JJ, Kuo FC, Wu JY, Wang WM, Bair MJ. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection. Helicobacter. 2007;12:633-637.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe